Invivyd, Inc. IVVD
Set alert
At close · Nov 2
After hours · Nov 2, 7:52 PM ET
- YTD
- -76.44%
- 1 year
- -66.93%
- Open
- 0.598
- Prev close
- 0.5817
- Mkt cap
- 171.55M
- Vol
- 4.43M
- Avg vol
- 5.09M
- EPS
- -0.33
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.55
- High
- 0.5995
- Forward P/E
- -2.36
- Beta
- 0.66
- Short ratio
- 23.71
- Inst. own
- 79.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 0.78992
- 200-d avg
- 1.55
- 1y target
- 5.89
5D chart
Signals (147)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 3:35 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 3:35 PM | 9 hours ago |
| SMA: Bearish | Nov 2, 3:30 PM | 9 hours ago |
| SMA: Bearish | Nov 2, 3:30 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 3:15 PM | 9 hours ago |
| SMA: Bearish | Nov 2, 3:10 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 3:05 PM | 9 hours ago |
| MACD: Buy Signal | Nov 2, 3:00 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 2:50 PM | 9 hours ago |
| SMA: Bearish | Nov 2, 2:45 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 2:40 PM | 10 hours ago |
| SMA: Bearish | Nov 2, 1:35 PM | 11 hours ago |
| MACD: Sell Signal | Nov 2, 1:20 PM | 11 hours ago |
| SMA: Bearish | Nov 2, 1:10 PM | 11 hours ago |
| SMA: Bullish | Nov 2, 12:40 PM | 12 hours ago |
| SMA: Bearish | Nov 2, 12:35 PM | 12 hours ago |
| SMA: Bullish | Nov 2, 12:25 PM | 12 hours ago |
| SMA: Bearish | Nov 2, 12:15 PM | 12 hours ago |
| MACD: Buy Signal | Nov 2, 11:40 AM | 13 hours ago |
| SMA: Bullish | Nov 2, 11:35 AM | 13 hours ago |
Newest 20 of 147.
Key statistics
- Market cap
- 56.35M
- Enterprise value
- -52.78M
- Trailing P/E
- 0.00
- Forward P/E
- -2.36
- PEG ratio
- 0.00
- Price / sales
- 24.89
- Price / book
- 0.29
- EPS (TTM)
- -1.95
- Beta
- 0.66
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 2.26M
- Revenue growth
- 0.00%
- Free cash flow
- -115.91M
- Total cash
- 147.88M
- Total debt
- 681.00K
- Return on equity
- -96.56%
- Shares outstanding
- 119.62M
- Short % of float
- 10.50%
- 50-day average
- 0.78992
- 200-day average
- 1.55
Analyst view
Consensus: buy
- Target (low)
- 1.00
- Target (mean)
- 5.89
- Target (high)
- 10.00
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.315.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.33 | -0.51 | -0.18 | -54.55% |
| Aug 14, 2024 | Jun 1, 2024 | -0.37 | -0.40 | -0.03 | -8.11% |
| Aug 14, 2024 | Jun 1, 2024 | -0.37 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.51 | -0.38 | +0.13 | +25.49% |
| May 9, 2024 | Mar 1, 2024 | -0.51 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | -0.41 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 21, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 20, 2024 | Morgan Stanley | main | Overweight | Overweight |
| Nov 20, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 14, 2024 | D. Boral Capital | main | Buy | Buy |
| Oct 30, 2024 | EF Hutton | init | — | Buy |
| Oct 29, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Invivyd, Inc.
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- invivyd.com
News
- Invivyd Presents Preclinical Data Showing Measles Antibody Candidate VMS063 Demonstrates Potent Antiviral Activity Against Contemporary Measles Fusion Protein Variants
- Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
- Invivyd And SPEAR Study Group Initiate FLINTLOCK Phase 2 Trial Evaluating Safety, Tolerability, Pharmacokinetics, And Clinical Efficacy Of High-Dose Monoclonal Antibody VYD2311 In Individuals With Long COVID Or Post-Vaccination Syndrome
- Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
- Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
- Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody
- Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody
- Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript
Your note
Sign in to keep a note on IVVD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADIMAB, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jan 18, 2024 | 21,687,900 |
| MCGUIRE TERRANCE G | Director | Sale | Dec 18, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Maverick Capital Ltd. | 9.84% | 11,765,787 | 5.54M | Sep 29, 2024 |
| Deep Track Capital, Lp | 9.16% | 10,953,937 | 5.16M | Sep 29, 2024 |
| M28 Capital Management LP | 7.73% | 9,248,250 | 4.36M | Sep 29, 2024 |
| FMR, LLC | 6.12% | 7,320,982 | 3.45M | Sep 29, 2024 |
| Blackrock Inc. | 3.91% | 4,671,723 | 2.20M | Sep 29, 2024 |
| Vanguard Group Inc | 3.65% | 4,365,769 | 2.06M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.50% | 2,986,726 | 1.41M | Sep 29, 2024 |
| Fidelity Growth Company Fund | 1.74% | 2,084,705 | 982.10K | Oct 30, 2024 |
| iShares Russell 2000 ETF | 1.34% | 1,604,111 | 755.70K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.68% | 811,105 | 382.11K | Aug 30, 2024 |
| Vanguard Extended Market Index Fund | 0.67% | 797,404 | 375.66K | Sep 29, 2024 |
| iShares Russell 2000 Value ETF | 0.60% | 719,024 | 338.73K | Oct 30, 2024 |